Metoclopramide G.L. Pharma

Metoclopramide, the active ingredient in Metoclopramide G.L. Pharma, is a dopamine antagonist presented as an injectable solution for intravenous use. It is employed to control nausea and vomiting, to enhance gastric motility in gastroparesis, and to mitigate chemotherapy‑induced and postoperative nausea in adult patients.

GNH USA supplies Metoclopramide G.L. Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The product meets EU quality standards and is manufactured under strict GMP conditions.

Metoclopramide acts on dopaminergic pathways that trigger nausea and on gastrointestinal motility, making it useful for several clinical conditions.

- Nausea and vomiting: reduces frequency and severity of episodes in diverse settings. - Post‑operative nausea and vomiting: prevents or treats nausea after surgical procedures. - Gastroparesis: accelerates gastric emptying and relieves symptoms of delayed stomach emptying. - Chemotherapy‑induced nausea: alleviates nausea associated with cytotoxic cancer treatment.

Metoclopramide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Drowsiness - Fatigue - Restlessness - Diarrhea - Headache

Serious or Rare Side Effects: - Tardive dyskinesia - Neuroleptic malignant syndrome - Seizures

Before initiating therapy, clinicians should consider several safety measures.

- Assess renal and hepatic function: adjust use in impairment. - Monitor for extrapyramidal symptoms: watch for involuntary movements. - Use the lowest effective dose and limit duration of therapy. - Avoid use in patients with known hypersensitivity to metoclopramide. - Contraindicated in patients with pheochromocytoma or seizure disorders. - Store at room temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antipsychotics: increase risk of extrapyramidal effects. - MAO inhibitors: may precipitate hypertensive crisis. - CYP2D6 inhibitors: raise metoclopramide plasma concentrations. - QT‑prolonging drugs: enhance risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Opioids: may enhance sedation. - CNS depressants: increase drowsiness. - Anticholinergic agents: reduce pro‑kinetic efficacy.